Physician profile
Abdul Khan
NPI 1295944163
$516.33
in general payments reported to CMS, 2019-2025
10 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.97 · 2022: $148 · 2023: $33.12 · 2024: $81.12 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.81 | 2021-2025 | |
| Janssen Biotech, INC. | $112.49 | 2022-2025 | Tremfya, Stelara, Remicade |
| Terumo Medical Corporation | $93.25 | 2022 | |
| Braintree Laboratories, INC. | $49.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.63 | 2024-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $24.36 | 2024 | |
| Intercept Pharmaceuticals, INC. | $22.91 | 2025 | |
| Madrigal Pharmaceuticals | $21.54 | 2025 | Rezdiffra |
| Sandoz INC. | $20.28 | 2025 | Hyrimoz |
| Apollo Endosurgery US INC | $13.89 | 2023 | Orbera Intragastric Balloon System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.